Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced national media coverage of its breast cancer vaccine on Fox News' 'Fox & Friends' and in the New York Post. The company's innovative vaccine aims to prevent breast cancer by targeting α-lactalbumin, a protein normally expressed only during lactation but also found in breast cancer cells. The vaccine is designed to train the immune system to identify and destroy cancerous cells before they develop into invasive tumors by activating cytotoxic T cells against cells expressing α-lactalbumin. This preventive approach could potentially revolutionize breast cancer treatment by providing preemptive immune protection against emerging breast tumors.

Positive

• Media exposure on major national outlets (Fox News and New York Post) increases visibility and potential investor interest
• Innovative approach targeting α-lactalbumin protein shows potential for breast cancer prevention
• Vaccine's selective targeting mechanism focuses only on cancer cells expressing specific protein

Negative

• None.

SAN JOSE, Calif., June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends." Both the New York Post and Fox News highlighted the potential of Anixa's vaccine to change the paradigm for breast cancer treatment and prevention.

Anixa's breast cancer vaccine is designed to train the immune system to recognize and eliminate cancerous cells before they can develop into invasive tumors. The vaccine targets a lactation protein, α-lactalbumin, which is only expressed in the breast when a woman is lactating but not at other times in her life or in other tissues. However, when a woman develops breast cancer many of the malignant cells will express α-lactalbumin. Activating the immune system, through vaccination, to direct cytotoxic T cells to the tumor cell expressing this protein may provide preemptive immune protection against emerging breast tumors that express α-lactalbumin.

The New York Post interview can be accessed here: https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/?utm_source=instagram&utm_medium=social&utm_campaign=nypost&utm_content=nypost_stories.

The Fox News "Fox & Friends" segment can be viewed here: https://www.foxnews.com/video/6374052231112.

A more comprehensive discussion of Anixa and its breast cancer vaccine, as well as its other development programs, can be reviewed at: https://ir.anixa.com/corporate-presentation.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-breast-cancer-vaccine-receives-national-news-coverage-302477184.html

SOURCE Anixa Biosciences, Inc.

FAQ

What is the mechanism of action for Anixa Biosciences' (ANIX) breast cancer vaccine?

The vaccine targets α-lactalbumin, a protein expressed during lactation and in breast cancer cells, training the immune system to eliminate cancer cells before they form tumors.

How does Anixa's (ANIX) breast cancer vaccine identify cancer cells?

It targets the α-lactalbumin protein, which is only present during lactation and in breast cancer cells, allowing selective targeting of malignant cells.

What major media coverage did Anixa Biosciences (ANIX) receive for its breast cancer vaccine?

The vaccine was featured on Fox News' 'Fox & Friends' and in the New York Post, highlighting its potential to change breast cancer treatment.

What is unique about Anixa Biosciences' (ANIX) approach to breast cancer prevention?

The vaccine provides preemptive immune protection by training the body to recognize and destroy cancer cells before they develop into invasive tumors.

Who is leading Anixa Biosciences' (ANIX) breast cancer vaccine development?

Dr. Amit Kumar, CEO of Anixa Biosciences, is leading the development and was interviewed about the vaccine by the New York Post.